Evidence map›Paper›PMID 42333464›Full record

ArticleIntegrative cancer therapies

Reporting Quality of Randomized Controlled Trials Published in

Geliang Yang, Shuting Guo, Feng Wen, Xu Han, Huiqing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Geliang YangDepartment of Clinical Research, Shanghai Clinical Research and Trial Center, ShanghaiTech University, Shanghai, China.ORCID 0000-0002-3878-2066
Shuting GuoDepartment of Traditional Chinese Medicine, Naval Medical University, Shanghai, China.
Feng WenCollege of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Xu HanDepartment of Stomatology, First Affiliated Hospital of Naval Medical University, Shanghai, China.
Huiqing ZhangDepartment of Traditional Chinese Medicine, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Consolidated Standards of Reporting Trials (CONSORT) 2025 Statement was issued in April 2025, however, no dedicated CONSORT extension currently exists for integrative oncology. It is therefore essential to provide practical recommendations, grounded in the CONSORT 2025 Statement and in an analysis of randomized controlled trials (RCT) reporting quality against CONSORT 2010, to guide future RCTs. This study presents a literature-based analysis of RCTs published in

Indexed as

Integrative OncologyNeoplasmsRandomized Controlled Trials as TopicHumansQuality ControlResearch DesignCONSORT statementintegrative oncologyqualityrandomized controlled trialreport

Identifiers

PMID42333464
PMCPMC13305783

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.